Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|November 2, 2021
Daily Medication Pearl: Benralizumab (Fasenra)
Author(s)Saro Arakelians, PharmD
Benralizumab (Fasenra) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.
Advertisement
Medication Pearl of the Day: Benralizumab (Fasenra)
Indication: Benralizumabis an interleukin-5 receptor (IL-5Rα) alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.
Insight:
- Dosing: Administer by subcutaneous injection. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter
- Dosage form: Injection 30 mg/mL solution in a single-dose prefilled syringe. Injection 30 mg/mL solution in a single dose autoinjector Fasenra Pen.
- Adverse events (AEs): Most common AEs are headache and pharyngitis.
- Mechanism of action: Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the IL-5Rα with a dissociation constant of 11 pM.
- Manufacturer: AstraZeneca
Sources:
Advertisement
Related to this article
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
4
Ramantamig's 93.6% ORR and Outpatient CRS Control
5